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CYP2D6 Genotype Should Not Be Used to 
Determine Endocrine Therapy in Postmenopausal 
Breast Cancer Patients
JM Rae1,2
The antiestrogen tamoxifen is an effec-
tive treatment for all stages of estrogen 
receptor (ER)-positive breast cancer.1 
Tamoxifen blocks estrogen-dependent 
breast cancer growth by competing 
with estrogen for binding to its receptor. 
Tamoxifen itself has antiestrogenic prop-
erties, but it is metabolized by a number 
of cytochrome P450 enzymes into many 
different metabolites that have varying 
degrees of antiestrogenic activity. Stud-
ies have consistently shown that cyto-
chrome P450 2D6 (CYP2D6), a highly 
polymorphic drug-metabolizing enzyme, 
is the enzyme primarily responsible for 
the production of one of the most potent 
metabolites, endoxifen (4-hydroxy-N-
desmethyl-tamoxifen). Preclinical stud-
ies of estrogen-dependent breast cancer 
have shown that endoxifen is an approxi-
mately 100-fold more potent antiestrogen 
than tamoxifen or the major tamoxifen 
metabolite, N-desmethyl-tamoxifen. 
Patients who are homozygous for two 
null CYP2D6 alleles, and are therefore 
poor metabolizers (PMs), as well as 
patients who are taking medications that 
are CYP2D6 inhibitors, have lower serum 
endoxifen concentrations as compared 
with patients who have one or more 
wild-type CYP2D6 alleles (intermediate 
metabolizers (IMs) and extensive metab-
olizers (EMs), respectively) (reviewed by 
Hertz et al.2).
These data led to the hypothesis that 
CYP2D6 PMs may not respond to tamox-
ifen therapy and that they may experi-
ence fewer side effects, compared with 
EMs, because they have lower circulating 
endoxifen levels. In an initial study test-
ing this hypothesis, the relapse-free time 
and disease-free survival were lower in 
CYP2D6 PMs than in EMs.3 This report 
spurred subsequent, highly heterogeneous 
studies of patients treated with tamoxifen. 
To date, the studies have produced very 
contradictory results, with some studies 
showing the hypothesized positive asso-
ciation between CYP2D6 genotype and 
tamoxifen response, others showing no 
association, and some even suggesting an 
inverse association.2 Most of these reports 
come from studies of convenience, repre-
senting quite low levels of evidence, and 
only a few of the studies utilized specimens 
collected and archived from prospectively 
conducted clinical trials, the gold standard 
for studies with a high level of evidence.
Despite this uncertainty, Ratain (as in 
his Counterpoint)4 and others argue that 
there is sufficient evidence to change clini-
cal practice to include CYP2D6 genotype 
in order to guide decisions regarding 
tamoxifen treatment in postmenopausal 
women with ER-positive breast cancer. 
Evidence in support of using CYP2D6 gen-
otype in this way comes largely from the 
study published by Schroth et al., which 
showed that PM patients had shorter 
event-free and disease-free survival, but 
not shorter overall survival, compared 
with IMs and EMs.5 This cohort, which 
did not contain a control group, represents 
a mixed data set of previously reported 
and new additional cases, using data sets of 
convenience and DNA derived from for-
malin-fixed, paraffin-embedded (FFPE) 
tumor, blood, and fresh-frozen tumor. 
Evidence against changing clinical practice 
to include CYP2D6 testing has been gen-
erated by a number of studies, including 
two prospective–retrospective studies—
by the Breast International Group (BIG) 
1-98 and the Arimidex, Tamoxifen, Alone 
or in Combination (ATAC) clinical tri-
alist—that failed to show an association 
between CYP2D6 genotype and clinical 
outcomes in tamoxifen-treated patients.6,7 
The strengths of these two studies include 
the large number of patients analyzed, the 
long-term and detailed clinical follow-up 
data within registration clinical trials, and 
the inclusion of control groups (patients 
receiving aromatase inhibitors, AIs). To 
date, the available clinical data do not 
achieve the level of evidence required 
to change clinical practice to include 
CYP2D6 genetic testing for women with 
ER-positive breast cancer considering 
adjuvant tamoxifen therapy.
Proponents of the CYP2D6–tamoxifen 
hypothesis have noted that the CYP2D6 
genotype data from BIG1-98 and ATAC 
are out of Hardy-Weinberg equilibrium 
(HWE) and raised concerns about the use 
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olution methodologies that fail to detect 
the specific genes within the large 22q13 
region that exhibit LOH. More recent 
studies conducting very-high-resolution 
fine genomic mapping to analyze much 
larger numbers of primary breast tumors 
have failed to show frequent LOH of the 
CYP2D6 locus in the majority of breast 
cancer tumor types. One study suggested 
occasional LOH in the CYP2D6 gene 
region, but this observation was confined 
to basal-like breast cancers, which are 
rarely ER-positive, and is therefore irrel-
evant in this debate.11
Finally, even if LOH in CYP2D6 were a 
frequent occurrence in ER-positive breast 
tumors that are available for genotyping, 
tumors always contain normal tissue that 
provides DNA containing two copies of 
each allele. Taken together, the data argue 
against Ratain’s concern that genotyping 
errors occurred in the studies that used 
FFPE tumor tissue for genotyping. His 
assertion that tumor LOH confounded 
germline CYP2D6 gene testing in the 
BIG1-98 study is a hypothesis that is wor-
thy of testing, but, unless it is proven, the 
hypothesis itself does not invalidate the 
data presented.
Other pharmacological concerns must 
also be considered in this debate. Tamox-
ifen is not a true “prodrug,” because the 
parent drug and the many other metabo-
lites that are produced independent of 
CYP2D6 have antiestrogenic activity. Fur-
thermore, even PM patients make some 
endoxifen that, combined with tamoxifen 
and its other metabolites, might be present 
at sufficient concentrations to block ER 
signaling. Despite the inconsistent clini-
cal data and these biological and pharma-
cokinetic considerations, Ratain and his 
colleagues maintain that all ER-positive 
patients should undergo CYP2D6 genotype 
tribution of CYP2D6 genotype and phe-
notypes across multiple different ethnic 
groups has been established. An examina-
tion of the CYP2D6 genotype frequencies 
and the distribution of their correspond-
ing CYP2D6 metabolic phenotypes in the 
major CYP2D6–tamoxifen studies dem-
onstrates that all fall within the expected 
range (Table 1). Earlier studies tested only 
a few CYP2D6 alleles, which nevertheless 
captured the majority of PM patients. In 
later studies, with more CYP2D6 alleles 
tested, a small number of additional PMs 
would be expected along with a better 
delineation between IMs and EMs. All 
studies have the expected CYP2D6 geno-
type and phenotype distributions based on 
the alleles that were assayed. Therefore, it is 
inconsistent to argue that HWE deviations 
invalidate the BIG1-98 and ATAC stud-
ies, but not the studies by Goetz et al. and 
Schroth et al., because they all apparently 
deviate from HWE. Given that all studies 
have the expected number of patients who 
are CYP2D6 PMs, IMs, and EMs, it is rea-
sonable to assume that they present valid 
CYP2D6 genotype data and that the differ-
ences in the associations between CYP2D6 
and tamoxifen response are due to factors 
other than genotype errors. These possible 
factors include differences in patient selec-
tion, disease stage, intrinsic subtype, addi-
tional treatments and medications, and the 
quality of the follow-up data.
Nonetheless, Ratain and colleagues have 
suggested that genotypes obtained from 
FFPE tumor tissue do not faithfully rep-
resent the germline DNA, in that somatic 
deletions due to loss of heterozygosity 
(LOH) of the CYP2D6 chromosomal 
locus (22q13) are well established in breast 
cancer.9 Earlier studies have provided evi-
dence for deletions of 22q13 in primary 
breast cancers,10 but they used low-res-
of archival tumor samples as the source of 
DNA. Although HWE testing is a com-
mon practice for assessing systematic 
genotyping errors, straightforward HWE 
testing for CYP2D6 is complicated by 
germline copy-number variations observed 
in CYP2D6 (mainly CYP2D6*5 gene dele-
tion and CYP2D6*2 gene amplifications) 
and by population admixture. Indeed, even 
if one considers HWE an indication of ade-
quate CYP2D6 genotype distribution, then 
the issue of deviation from HWE is com-
mon to many CYP2D6 tamoxifen studies. 
For example, in the study by Goetz et al.,3 
although not reported, one can calculate 
a significant deviation from HWE with 
CYP2D6*4 (c2 = 13.5, P = 0.00024). An 
early report by Schroth et al., representing a 
German data set not taken from a prospec-
tive trial, states that “Two polymorphisms, 
CYP2D6*10 and CYP2C9*2, were not in 
Hardy-Weinberg equilibrium”; however, 
the specific CYP2D6 genotype data are 
not provided, prohibiting independent 
analyses of HWE.8 In what purports to 
be a larger validation study,5 the cohorts 
previously reported by Goetz et al.3 and 
Schroth et al.8 were combined with addi-
tional samples from a hospital registry. 
Not unexpectedly, statistically significant 
departures from HWE in CYP2D6*4 (c2 
= 6.9, P = 0.00855) and CYP2D6*10 (c2 = 
27.4, P = 1.65 × 10-7) were observed.5 Thus, 
lack of HWE is present both in studies sup-
porting an association between CYP2D6 
and tamoxifen and in those not supporting 
such an association.
In all pharmacogenetic studies, it is of 
primary importance that the genotype 
data be as accurate as possible, and in the 
case of CYP2D6, they should accurately 
represent a patient’s CYP2D6 metabolic 
phenotype. CYP2D6 is one of the most 
widely studied P450 enzymes, and the dis-
Table 1  CYP2D6 genotype frequencies and distribution of corresponding CYP2D6 metabolic phenotypes in the major  
CYP2D6–tamoxifen studies
CYP2D6 phenotype
study pm im em CYP2D6 alleles tested
Goetz et al.3 6.8 21.1 72.1 *4, *6
Schroth et al.8 7.1 33.0 59.9 *4, *5, *10, *41
Schroth et al.5 6.0 48.1 46.0 *3, *4, *5, *10, *41, XN
Rae et al.7 6.5 39.6 53.9 *2, *3, *4, *6, *10, *41
Regan et al.6 8.3 29.5 62.2 *3, *4, *6, *7, *17, 
EM, extensive metabolizer; IM, intermediate metabolizer; PM, poor metabolizer.
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of evidence addressing this issue are desir-
able, until they become available CYP2D6 
genetic testing should not be introduced 
into routine clinical practice to guide the 
decision as to whether a patient should 
receive tamoxifen therapy.
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to guide adjuvant endocrine therapy. Given 
that several studies (including ATAC and 
BIG1-98) have demonstrated that the AIs 
are slightly more effective than tamoxifen,1 
one could argue that we should abandon 
tamoxifen altogether and that all post-
menopausal women should receive AI 
therapy. However, these arguments ignore 
the extensive use of tamoxifen in premeno-
pausal women (for whom AIs are contrain-
dicated) and for postmenopausal women 
who cannot tolerate an AI (which may 
exceed 30% of those treated). A decade 
ago, we hypothesized that CYP2D6 geno-
type could help guide antiestrogen therapy 
decisions based on sound pharmacokinetic 
data. However, in retrospect, this hypoth-
esis appears to be based on a weak biologi-
cal underpinning, and the available clinical 
data are insufficient to support it.
In conclusion, to date, the weight of all 
available evidence argues against the use of 
CYP2D6 genotype testing for women con-
sidering tamoxifen. Although higher levels 
CYP2D6 Genotype and Tamoxifen Activity: 
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There has been great controversy over 
the years regarding the impact of 
CYP2D6 polymorphisms on the efficacy 
of tamoxifen in women with breast 
cancer. The most significant publication 
to date is the report by investigators in 
Stuttgart, Germany, and at the Mayo 
Clinic of a 1,325-patient study, published 
in 2009 in the Journal of the American 
Medical Association.1 Despite this high-
impact publication, there has been 
variable acceptance of these findings 
because of inconsistent replication of 
the results.2
The controversy
Are the studies demonstrating an asso-
ciation between CYP2D6 genotype and 
tamoxifen efficacy false-positive studies? 
We acknowledge that false-positive stud-
ies are endemic in the pharmacogenomic 
literature, generally because of failure to 
correct for multiple testing of associa-
tions between a large number of candidate 
polymorphisms and multiple phenotypes. 
However, this concern is not applicable to 
the study by Schroth and colleagues1 or 
most of the other positive studies that have 
focused exclusively on testing of a single 
polymorphic gene, CYP2D6. Furthermore, 
although some of these positive studies 
have modest sample sizes and/or incom-
plete genotyping, those factors would not 
affect the probability that a positive study 
is a true positive (but would increase the 
probability of a false-negative study).
Or are the studies that failed to 
demonstrate such an association false-
negative studies? If so, what would be the 
explanation? False-negative replication 
studies can occur for many reasons. One 
often focuses on statistical explanations 
for failure of replication. For example, 
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